JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

Search

Microbot Medical Inc

Deschisă

1.8 0.56

Rezumat

Modificarea prețului

24h

Curent

Minim

1.76

Maxim

1.8399999999999999

Indicatori cheie

By Trading Economics

Venit

-77K

-3.6M

Angajați

20

EBITDA

-79K

-3.6M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+386.11% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-11M

129M

Deschiderea anterioară

1.24

Închiderea anterioară

1.8

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Microbot Medical Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb. 2026, 23:23 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb. 2026, 22:57 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb. 2026, 21:51 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 feb. 2026, 21:49 UTC

Câștiguri

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb. 2026, 21:39 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:36 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb. 2026, 21:34 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:28 UTC

Achiziții, Fuziuni, Preluări

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 21:23 UTC

Câștiguri

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb. 2026, 21:19 UTC

Câștiguri

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:10 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:08 UTC

Câștiguri

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb. 2026, 21:07 UTC

Câștiguri

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q EPS 24c >PLTR

2 feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparație

Modificare preț

Microbot Medical Inc Așteptări

Obiectiv de preț

By TipRanks

386.11% sus

Prognoză pe 12 luni

Medie 8.75 USD  386.11%

Maxim 12 USD

Minim 5.5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMicrobot Medical Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.52 / 2.57Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat